search
Back to results

Tranexamic Acid Effect on Digit Function Following Primary Repair of Traumatic Digit Flexor Tendon Injuries

Primary Purpose

Tendon Injury - Hand

Status
Unknown status
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Tranexamic acid injection
PLACEBO
Sponsored by
Rabin Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tendon Injury - Hand focused on measuring Tendon Injury, Tranexamic Acid

Eligibility Criteria

18 Years - 120 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients that will undergo surgical repair of traumatic zone 1 or zone 2 digit flexor tendon tears

Exclusion Criteria:

  • Age < 18
  • Pregnant Women
  • Patients that presented 3 weeks or later after the injury
  • Medical history positive for Rheumatic disease
  • Current active treatment with anti-coagulation medications
  • Injury to more than one finger
  • Presence of a fracture in the affected finger
  • Presence of a nerve injury in the affected finger that won't enable early use and activation in early rehabilitation protocol
  • Mangled extremity injury, degloving injury or other soft tissue injuries that won't enable primary closure of skin
  • Previous tear of the affected tendon
  • Degenerative tear of flexor tendon
  • Tendon tear secondary to infection
  • Previous injuries to contralateral side causing dysfunction and/or decreased fingers' range of motion
  • Contraindications to Tranexamic acid treatment:

    • Known hypersensitivity to tranexamic acid or to any other ingredient of the preparation.
    • Patients with thromboembolic disease.
    • Patients with active intravascular clotting.
    • Severe renal failure because of risk of accumulation.
    • Patients with subarachnoid hemorrhage
    • Patients with acquired defective color vision

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Tranexamic Acid Treatment

    Placebo

    Arm Description

    1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION

    10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION

    Outcomes

    Primary Outcome Measures

    Anatomic Result at 4-Months post-operatively
    Measurement of the anatomical outcome for both Zone1 and Zone 2 tears will be achieved by measuring the Total Active Motion (TAM) using the American Society for Surgery of the Hand Criteria (ASSH). Active flexion of the MCPJ, PIP and DIP joints are measured in degrees, and summed. Extension deficits in these joints are measured in degrees, summed, and deducted from the flexion measurements. The full TAM of a finger is 260 degrees: MCPJ 85 degrees, PIPJ 110 degrees and DIPJ 65 degrees The TAM of the affected side can be compared to the normal contralateral side, and expressed as percentage of return of motion. The Change of the TAM from baseline will be recorded for at the planned serial follow-ups, as described below.

    Secondary Outcome Measures

    Anatomic Result at 2-weeks and 8-weeks post-operatively
    Measurement of the anatomical outcome for both Zone1 and Zone 2 tears will be achieved by measuring the Total Active Motion (TAM) using the American Society for Surgery of the Hand Criteria (ASSH). Active flexion of the MCPJ, PIP and DIP joints are measured in degrees, and summed. Extension deficits in these joints are measured in degrees, summed, and deducted from the flexion measurements. The full TAM of a finger is 260 degrees: MCPJ 85 degrees, PIPJ 110 degrees and DIPJ 65 degrees The TAM of the affected side can be compared to the normal contralateral side, and expressed as percentage of return of motion. The Change of the TAM from baseline to each post-operative follow up will be recorded.
    Extent of finger and hand swelling
    Estimation of finger and hand swelling will be achieved by calculating a Swelling-Ratio (SR). Direct measurement of the circumference of both the affected and unaffected finger and hand palm will be made. Finger circumference will be measured in two anatomic locations: the middle of both the proximal and middle phalanx. Hand circumference will be measured on the level of the distal palmar crease. Above measurements will be documented in centimeters. The SR will be calculated by dividing the circumference of the affected side by the circumference of the unaffected side.
    Strength Result
    Grip Strength is a widely-used clinical assessment tool , which gives a good global assessment of muscle strength, and delineates the impact of tendon injury on overall strength. After flexor tendon repair, impairments are more common in isolated finger flexion than in overall handgrip strength. overall grip strength is the mainstay of strength assessment. There are several standardized protocols to assess grip strength, one is performing the measurement with the elbow flexed 90 degrees, the forearm in neutral, and the Patient gripping the Jamar dynamometer at the second handle position. Estimation of hand grip strength will be achieved by calculating a Grip Strength-Ratio (GSR). Direct measurement of the Grip strength of both the affected and unaffected hands will be made. Above measurements will be documented in kilograms. The GSR will be calculated by dividing the grip strength of the affected hand by the grip strength of the unaffected side.
    Functional Result - DASH Score
    Functional Evaluation will be achieved using the DASH (Disabilities of the Arm, Shoulder and Hand) Questionnaire. The DASH Score is the current most practiced scale for upper extremity functionality, and was extensively validated in numerous studies. The Scale ranges from 0 (no disability) to 100 (most severe disability).
    Functional Result - PRWE Score
    Functional Evaluation will be achieved using the PRWE (Patient-Rated Wrist Evaluation) Questionnaire. The PRWE was originally developed in 1998 as a measure of patient-rated pain and disability, following Distal Radius or Scaphoid Fractures. The Scale ranges from 0 (no disability) to 100 (most severe disability).

    Full Information

    First Posted
    November 1, 2019
    Last Updated
    November 24, 2019
    Sponsor
    Rabin Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04178655
    Brief Title
    Tranexamic Acid Effect on Digit Function Following Primary Repair of Traumatic Digit Flexor Tendon Injuries
    Official Title
    Range of Motion and Function Following Primary Repair of Traumatic Zone 1 or Zone 2 Digit Flexor Tendon Injuries - Impact of Tranexamic Acid Use - A Prospective Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2019
    Overall Recruitment Status
    Unknown status
    Study Start Date
    November 2019 (Anticipated)
    Primary Completion Date
    November 2022 (Anticipated)
    Study Completion Date
    March 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Rabin Medical Center

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No

    5. Study Description

    Brief Summary
    This study evaluates the effect of pre-operative treatment with IV Tranexamic Acid on post-operative digit function, in patients that underwent surgical repair of traumatic zone 1 or zone 2 digit flexor tendon tear.
    Detailed Description
    Peritendinous adhesions following repair of digital flexor tendons are a major postoperative complication, due to loss of motion and the functional disability that they cause. Patients who will present to Rabin Medical Center with acute traumatic Zone 1 or Zone 2 Digit flexor tendon injury, will be recruited to the study, given the patients' informed consent. Patients recruited to the study will be randomly assigned to either the study group or control group: Study Group - Intra-venous Tranexamic acid treatment Control Group - Placebo (Intra-venous normal saline 0.9%) All patients will be treated operatively with primary repair of the lacerated flexor tendon. All patients will be treated post-operatively with early controlled mobilization according to the Duran Protocol. Randomization of the patients will take place before surgery, in the following manner: half of the study population will be treated with IV Tranexamic Acid , the other half will be treated with or IV Normal Saline as Placebo. Either Tranexamic Acid or IV Normal Saline will be administered by the anesthesiologist present in the operating room, prior to tourniquet inflation. Each patient will be assigned a serial number, and 2 envelopes allocated to that serial number will be prepared in advance. The first envelope will be attached to the patient's file, and be given only to the anesthesiologist in the operating room. The second envelope assigned to the patient will remain closed until the end of the study, along with the study's documents. All study patients and hand surgeons will be blinded to the treatment received by the study population. Post-Operative measurements will be made by an orthopedic surgeon or occupational therapist, which will also be blinded to the treatment received by the study population. To ensure confidentiality, all study documents and data will be kept inside a locked closet, in a locked room in the orthopedic department

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Tendon Injury - Hand
    Keywords
    Tendon Injury, Tranexamic Acid

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Early Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    48 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Tranexamic Acid Treatment
    Arm Type
    Experimental
    Arm Description
    1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
    Intervention Type
    Drug
    Intervention Name(s)
    Tranexamic acid injection
    Intervention Description
    1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
    Intervention Type
    Drug
    Intervention Name(s)
    PLACEBO
    Intervention Description
    10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
    Primary Outcome Measure Information:
    Title
    Anatomic Result at 4-Months post-operatively
    Description
    Measurement of the anatomical outcome for both Zone1 and Zone 2 tears will be achieved by measuring the Total Active Motion (TAM) using the American Society for Surgery of the Hand Criteria (ASSH). Active flexion of the MCPJ, PIP and DIP joints are measured in degrees, and summed. Extension deficits in these joints are measured in degrees, summed, and deducted from the flexion measurements. The full TAM of a finger is 260 degrees: MCPJ 85 degrees, PIPJ 110 degrees and DIPJ 65 degrees The TAM of the affected side can be compared to the normal contralateral side, and expressed as percentage of return of motion. The Change of the TAM from baseline will be recorded for at the planned serial follow-ups, as described below.
    Time Frame
    Documentation will take place pre-operatively, and 4-months post-operatively during out-patient clinic follow-up.
    Secondary Outcome Measure Information:
    Title
    Anatomic Result at 2-weeks and 8-weeks post-operatively
    Description
    Measurement of the anatomical outcome for both Zone1 and Zone 2 tears will be achieved by measuring the Total Active Motion (TAM) using the American Society for Surgery of the Hand Criteria (ASSH). Active flexion of the MCPJ, PIP and DIP joints are measured in degrees, and summed. Extension deficits in these joints are measured in degrees, summed, and deducted from the flexion measurements. The full TAM of a finger is 260 degrees: MCPJ 85 degrees, PIPJ 110 degrees and DIPJ 65 degrees The TAM of the affected side can be compared to the normal contralateral side, and expressed as percentage of return of motion. The Change of the TAM from baseline to each post-operative follow up will be recorded.
    Time Frame
    Serial documentation will take place pre-operatively, and post-operatively during out-patient clinic follow-ups on a planned basis at 2-weeks and 8-weeks post-operatively.
    Title
    Extent of finger and hand swelling
    Description
    Estimation of finger and hand swelling will be achieved by calculating a Swelling-Ratio (SR). Direct measurement of the circumference of both the affected and unaffected finger and hand palm will be made. Finger circumference will be measured in two anatomic locations: the middle of both the proximal and middle phalanx. Hand circumference will be measured on the level of the distal palmar crease. Above measurements will be documented in centimeters. The SR will be calculated by dividing the circumference of the affected side by the circumference of the unaffected side.
    Time Frame
    Serial documentation will take place pre-operatively, and post-operatively during out-patient clinic follow-ups on a planned basis: 2-weeks, 8-weeks, and 4-months post-operatively.
    Title
    Strength Result
    Description
    Grip Strength is a widely-used clinical assessment tool , which gives a good global assessment of muscle strength, and delineates the impact of tendon injury on overall strength. After flexor tendon repair, impairments are more common in isolated finger flexion than in overall handgrip strength. overall grip strength is the mainstay of strength assessment. There are several standardized protocols to assess grip strength, one is performing the measurement with the elbow flexed 90 degrees, the forearm in neutral, and the Patient gripping the Jamar dynamometer at the second handle position. Estimation of hand grip strength will be achieved by calculating a Grip Strength-Ratio (GSR). Direct measurement of the Grip strength of both the affected and unaffected hands will be made. Above measurements will be documented in kilograms. The GSR will be calculated by dividing the grip strength of the affected hand by the grip strength of the unaffected side.
    Time Frame
    Serial documentation will take place post-operatively during out-patient clinic follow-ups on a planned basis: 2-weeks, 8-weeks, and 4-months post-operatively.
    Title
    Functional Result - DASH Score
    Description
    Functional Evaluation will be achieved using the DASH (Disabilities of the Arm, Shoulder and Hand) Questionnaire. The DASH Score is the current most practiced scale for upper extremity functionality, and was extensively validated in numerous studies. The Scale ranges from 0 (no disability) to 100 (most severe disability).
    Time Frame
    Serial documentation will take place post-operatively during out-patient clinic follow-ups on a planned basis: 2-weeks, 8-weeks, and 4-months post-operatively.
    Title
    Functional Result - PRWE Score
    Description
    Functional Evaluation will be achieved using the PRWE (Patient-Rated Wrist Evaluation) Questionnaire. The PRWE was originally developed in 1998 as a measure of patient-rated pain and disability, following Distal Radius or Scaphoid Fractures. The Scale ranges from 0 (no disability) to 100 (most severe disability).
    Time Frame
    Serial documentation will take place post-operatively during out-patient clinic follow-ups on a planned basis: 2-weeks, 8-weeks, and 4-months post-operatively.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    120 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Patients that will undergo surgical repair of traumatic zone 1 or zone 2 digit flexor tendon tears Exclusion Criteria: Age < 18 Pregnant Women Patients that presented 3 weeks or later after the injury Medical history positive for Rheumatic disease Current active treatment with anti-coagulation medications Injury to more than one finger Presence of a fracture in the affected finger Presence of a nerve injury in the affected finger that won't enable early use and activation in early rehabilitation protocol Mangled extremity injury, degloving injury or other soft tissue injuries that won't enable primary closure of skin Previous tear of the affected tendon Degenerative tear of flexor tendon Tendon tear secondary to infection Previous injuries to contralateral side causing dysfunction and/or decreased fingers' range of motion Contraindications to Tranexamic acid treatment: Known hypersensitivity to tranexamic acid or to any other ingredient of the preparation. Patients with thromboembolic disease. Patients with active intravascular clotting. Severe renal failure because of risk of accumulation. Patients with subarachnoid hemorrhage Patients with acquired defective color vision

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    De-identified individual participant data will be made available
    IPD Sharing Time Frame
    within 6 months of study completion
    IPD Sharing Access Criteria
    requests will be reviewed by an external independent review panel. Requestors will be required to sign a Data Access Agreement.
    Citations:
    PubMed Identifier
    25934203
    Citation
    Pulos N, Bozentka DJ. Management of complications of flexor tendon injuries. Hand Clin. 2015 May;31(2):293-9. doi: 10.1016/j.hcl.2014.12.004. Epub 2015 Feb 28.
    Results Reference
    background
    PubMed Identifier
    28709791
    Citation
    Legrand A, Kaufman Y, Long C, Fox PM. Molecular Biology of Flexor Tendon Healing in Relation to Reduction of Tendon Adhesions. J Hand Surg Am. 2017 Sep;42(9):722-726. doi: 10.1016/j.jhsa.2017.06.013. Epub 2017 Jul 12.
    Results Reference
    background
    PubMed Identifier
    19395470
    Citation
    Khanna A, Friel M, Gougoulias N, Longo UG, Maffulli N. Prevention of adhesions in surgery of the flexor tendons of the hand: what is the evidence? Br Med Bull. 2009;90:85-109. doi: 10.1093/bmb/ldp013. Epub 2009 Apr 24.
    Results Reference
    background
    PubMed Identifier
    15634833
    Citation
    Sharma P, Maffulli N. Tendon injury and tendinopathy: healing and repair. J Bone Joint Surg Am. 2005 Jan;87(1):187-202. doi: 10.2106/JBJS.D.01850.
    Results Reference
    background
    PubMed Identifier
    21248211
    Citation
    Ishiyama N, Moro T, Ohe T, Miura T, Ishihara K, Konno T, Ohyama T, Kimura M, Kyomoto M, Saito T, Nakamura K, Kawaguchi H. Reduction of Peritendinous adhesions by hydrogel containing biocompatible phospholipid polymer MPC for tendon repair. J Bone Joint Surg Am. 2011 Jan 19;93(2):142-9. doi: 10.2106/JBJS.I.01634.
    Results Reference
    background
    PubMed Identifier
    7605612
    Citation
    Murphy PG, Loitz BJ, Frank CB, Hart DA. Influence of exogenous growth factors on the synthesis and secretion of collagen types I and III by explants of normal and healing rabbit ligaments. Biochem Cell Biol. 1994 Sep-Oct;72(9-10):403-9. doi: 10.1139/o94-054.
    Results Reference
    background
    PubMed Identifier
    26942474
    Citation
    Lin ZX, Woolf SK. Safety, Efficacy, and Cost-effectiveness of Tranexamic Acid in Orthopedic Surgery. Orthopedics. 2016 Mar-Apr;39(2):119-30. doi: 10.3928/01477447-20160301-05. Epub 2016 Mar 4.
    Results Reference
    background
    PubMed Identifier
    25944156
    Citation
    Aguilera X, Martinez-Zapata MJ, Hinarejos P, Jordan M, Leal J, Gonzalez JC, Monllau JC, Celaya F, Rodriguez-Arias A, Fernandez JA, Pelfort X, Puig-Verdie Ll. Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial. Arch Orthop Trauma Surg. 2015 Jul;135(7):1017-25. doi: 10.1007/s00402-015-2232-8. Epub 2015 May 7.
    Results Reference
    background
    PubMed Identifier
    20554319
    Citation
    CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14.
    Results Reference
    background
    PubMed Identifier
    23651507
    Citation
    Gandhi R, Evans HM, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes. 2013 May 7;6:184. doi: 10.1186/1756-0500-6-184.
    Results Reference
    background
    PubMed Identifier
    21999623
    Citation
    McConnell JS, Shewale S, Munro NA, Shah K, Deakin AH, Kinninmonth AW. Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray. Acta Orthop. 2011 Dec;82(6):660-3. doi: 10.3109/17453674.2011.623568. Epub 2011 Oct 17.
    Results Reference
    background
    PubMed Identifier
    16470437
    Citation
    Niskanen RO, Korkala OL. Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis. Acta Orthop. 2005 Dec;76(6):829-32. doi: 10.1080/17453670510045444.
    Results Reference
    background
    PubMed Identifier
    23614539
    Citation
    Oremus K, Sostaric S, Trkulja V, Haspl M. Influence of tranexamic acid on postoperative autologous blood retransfusion in primary total hip and knee arthroplasty: a randomized controlled trial. Transfusion. 2014 Jan;54(1):31-41. doi: 10.1111/trf.12224. Epub 2013 Apr 25.
    Results Reference
    background
    PubMed Identifier
    24799144
    Citation
    Frueh FS, Kunz VS, Gravestock IJ, Held L, Haefeli M, Giovanoli P, Calcagni M. Primary flexor tendon repair in zones 1 and 2: early passive mobilization versus controlled active motion. J Hand Surg Am. 2014 Jul;39(7):1344-50. doi: 10.1016/j.jhsa.2014.03.025. Epub 2014 May 5.
    Results Reference
    background
    PubMed Identifier
    8515007
    Citation
    Jansen CW, Watson MG. Measurement of range of motion of the finger after flexor tendon repair in zone II of the hand. J Hand Surg Am. 1993 May;18(3):411-7. doi: 10.1016/0363-5023(93)90083-f.
    Results Reference
    background
    PubMed Identifier
    7430595
    Citation
    Strickland JW, Glogovac SV. Digital function following flexor tendon repair in Zone II: A comparison of immobilization and controlled passive motion techniques. J Hand Surg Am. 1980 Nov;5(6):537-43. doi: 10.1016/s0363-5023(80)80101-8.
    Results Reference
    background
    PubMed Identifier
    23660061
    Citation
    Tang JB. Outcomes and evaluation of flexor tendon repair. Hand Clin. 2013 May;29(2):251-9. doi: 10.1016/j.hcl.2013.02.007.
    Results Reference
    background
    PubMed Identifier
    12945647
    Citation
    Elliot D, Harris SB. The assessment of flexor tendon function after primary tendon repair. Hand Clin. 2003 Aug;19(3):495-503. doi: 10.1016/s0749-0712(03)00028-3.
    Results Reference
    background
    PubMed Identifier
    15891987
    Citation
    MacDermid JC. Measurement of health outcomes following tendon and nerve repair. J Hand Ther. 2005 Apr-Jun;18(2):297-312. doi: 10.1197/j.jht.2005.02.009.
    Results Reference
    background
    PubMed Identifier
    8773720
    Citation
    Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). Am J Ind Med. 1996 Jun;29(6):602-8. doi: 10.1002/(SICI)1097-0274(199606)29:63.0.CO;2-L. Erratum In: Am J Ind Med 1996 Sep;30(3):372.
    Results Reference
    background
    PubMed Identifier
    21159335
    Citation
    Hoang-Kim A, Pegreffi F, Moroni A, Ladd A. Measuring wrist and hand function: common scales and checklists. Injury. 2011 Mar;42(3):253-8. doi: 10.1016/j.injury.2010.11.050. Epub 2010 Dec 15.
    Results Reference
    background
    PubMed Identifier
    17168270
    Citation
    Libberecht K, Lafaire C, Van Hee R. Evaluation and functional assessment of flexor tendon repair in the hand. Acta Chir Belg. 2006 Sep-Oct;106(5):560-5. doi: 10.1080/00015458.2006.11679952.
    Results Reference
    background
    PubMed Identifier
    27418884
    Citation
    Dacombe PJ, Amirfeyz R, Davis T. Patient-Reported Outcome Measures for Hand and Wrist Trauma: Is There Sufficient Evidence of Reliability, Validity, and Responsiveness? Hand (N Y). 2016 Mar;11(1):11-21. doi: 10.1177/1558944715614855. Epub 2016 Jan 13.
    Results Reference
    background
    PubMed Identifier
    9840793
    Citation
    MacDermid JC, Turgeon T, Richards RS, Beadle M, Roth JH. Patient rating of wrist pain and disability: a reliable and valid measurement tool. J Orthop Trauma. 1998 Nov-Dec;12(8):577-86. doi: 10.1097/00005131-199811000-00009.
    Results Reference
    background

    Learn more about this trial

    Tranexamic Acid Effect on Digit Function Following Primary Repair of Traumatic Digit Flexor Tendon Injuries

    We'll reach out to this number within 24 hrs